欢迎来到天天文库
浏览记录
ID:9455585
大小:913.90 KB
页数:6页
时间:2018-05-01
《盐酸阿那格雷胶囊治疗原发性血小板增多症的有效性和安全性——多中心、随机对照临床研究》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、生垡血.煎堂盘盍2Q15生!旦簋3§鲞箜2期些i!』H!盟i趔:血!Y2Q15,YQ!:3§:№:2·547·论著·盐酸阿那格雷胶囊治疗原发性血小板增多症的有效性和安全性——多中心、随机对照临床研究葛晓燕杨林花金洁钱文斌李建勇杨仁池曹祥山江滨王昭侯明张伟华肖中平赵永强高大张晓红王树叶孙爱宁傅晋翔苏力李康【摘要】目的评价阿那格雷治疗原发性血小板增多症(ET)的有效性和安全性。方法将符合WHO2008诊断标准的ET患者随机分配到阿那格雷组和羟基脲组。阿那格雷由2mg/d始逐渐增加,最大剂量为10mg/d,维持PLT(100~400)×109/L1个月后
2、,逐渐减量维持。羟基脲由1000mg/d逐渐增加,维持PLT(100~400)×109/L1个月后,减量至10mg·kg~·d-i维持。共观察12周。结果17个中心共人组222例ET患者(阿那格雷组、羟基脲组分别为113、109例),198例可评价疗效(阿那格雷组、羟基脲组分别为97、101例)。治疗12周,阿那格雷组血液学缓解率为87.63%(85197),羟基脲组为88.12%(89/101),差异无统计学意义(P=0.174)。阿那格雷组治疗前中位PLT为827(562~1657)×109IL,治疗12周为400(127~1130)×109/
3、L,差异有统计学意义(P4、似,起效时间较短,元明显血液学毒性,安全性较好。【关键词】血小板增多,原发性;阿那格雷;羟基脲;治疗,临床研究性;药物毒性Efficacyandsafetyofanagrelideintreatmentofessentialthrombocythemia:multicenter,randomizedcontrolledclinicaltrialGeXiaoyan,YangLinhuajJinJie,QianWenbin,LiJianyong,勋馏Renchi,CaoXiangshan÷JiangBin?WangZhao?HouMing,ZhangW5、eihuajXiaoZhongping,ZhaoYongqiangjGaoDa,ZhangXiaohong,WangShuye,SunAining,FuJinxiang,sun,nKnHg."DepartmentofHematology,theSecondHospitafofShanxiMedicalUniversity,Taiyuan030001。ChinaCorrespondingauthor.‘YangLinhua.Email:yanglh5282@i63.com【Abstract】0bieetiveToevaluatetheefficacy6、andsafetyofanagrelideinessentialthrombocythemia(ET).MethodsPatientswhodiagnosedasETaccordingtotheWorldHealthOrganizationclassificationwereenrolled.Eachpatientwasassignedtotakeanagrelidehydrochloridecapsuleorhydroxyureatabletbyrandom1:1ratio.DOSCofanagrelidestartedat2mg/d.theni7、ncreasedgraduallyandthemaximumdosewas10mg/duntiltheplateletcountsdroppedto(100-400)×l09/L,onemonthlatergraduallyreducedtomaintaindoseThedoseofhydroxyureawas1000mg/datbeginning,thenincreasedgradually,whenplateletcountsdroppedto(100-400)×l09/Landkeptforonemonth,reducedtomaintain8、doseas10mg·kg~·d—I.Theobservationperiodwas12weeks.ResultsAtot
4、似,起效时间较短,元明显血液学毒性,安全性较好。【关键词】血小板增多,原发性;阿那格雷;羟基脲;治疗,临床研究性;药物毒性Efficacyandsafetyofanagrelideintreatmentofessentialthrombocythemia:multicenter,randomizedcontrolledclinicaltrialGeXiaoyan,YangLinhuajJinJie,QianWenbin,LiJianyong,勋馏Renchi,CaoXiangshan÷JiangBin?WangZhao?HouMing,ZhangW
5、eihuajXiaoZhongping,ZhaoYongqiangjGaoDa,ZhangXiaohong,WangShuye,SunAining,FuJinxiang,sun,nKnHg."DepartmentofHematology,theSecondHospitafofShanxiMedicalUniversity,Taiyuan030001。ChinaCorrespondingauthor.‘YangLinhua.Email:yanglh5282@i63.com【Abstract】0bieetiveToevaluatetheefficacy
6、andsafetyofanagrelideinessentialthrombocythemia(ET).MethodsPatientswhodiagnosedasETaccordingtotheWorldHealthOrganizationclassificationwereenrolled.Eachpatientwasassignedtotakeanagrelidehydrochloridecapsuleorhydroxyureatabletbyrandom1:1ratio.DOSCofanagrelidestartedat2mg/d.theni
7、ncreasedgraduallyandthemaximumdosewas10mg/duntiltheplateletcountsdroppedto(100-400)×l09/L,onemonthlatergraduallyreducedtomaintaindoseThedoseofhydroxyureawas1000mg/datbeginning,thenincreasedgradually,whenplateletcountsdroppedto(100-400)×l09/Landkeptforonemonth,reducedtomaintain
8、doseas10mg·kg~·d—I.Theobservationperiodwas12weeks.ResultsAtot
此文档下载收益归作者所有